Nancy is the previous President of MSI Methylation Sciences, a private venture-backed development company with a novel treatment of depression in Phase II development. She is a former Partner and Senior Vice President of Ventures West Management Inc. During her tenure there, the life sciences portfolio grew from 0% of the overall investment portfolio to 30%. The firm grew from about $90M under management to about $750M in eight historical funds. Nancy participated in more than 30 investments and specialized in helping Canadian life sciences companies raise Series B rounds through accessing US venture capital funds. Some of these investments include companies such as Angiotech Pharmaceuticals, AnorMed, Caprion Pharmaceuticals, Celator Technologies, and many other biotechnology firms.